Eculizumab treatment for rescue of renal function in IgA nephropathy
- 1.1k Downloads
Immunoglobulin A (IgA) nephropathy is a chronic glomerulonephritis with excessive glomerular deposition of IgA1, C3 and C5b-9, which may lead to renal failure.
We describe the clinical course of an adolescent with rapidly progressive disease leading to renal failure in spite of immunosuppressive treatment. Due to refractory disease the patient was treated with eculizumab (anti-C5) for 3 months in an attempt to rescue renal function. Treatment led to clinical improvement with stabilization of the glomerular filtration rate and reduced proteinuria. Discontinuation of treatment led to a rapid deterioration of renal function. This was followed by a single dose of eculizumab, which again reduced creatinine levels temporarily.
Early initiation of eculizumab therapy in patients with progressive IgA nephropathy may have a beneficial effect by blocking complement-mediated renal inflammation.
KeywordsIgA nephropathy Complement Eculizumab
This study was supported by the Swedish Research Council (Grant K2013-64X-14008), The Torsten Söderberg Foundation, Crown Princess Lovisa’s Society for Child Care, The Konung Gustaf V:s 80-årsfond (all to DK). MJ is supported by the Marianne & Marcus Wallenberg Foundation, The Swedish Kidney Disease Association and Malmö University Hospital Research Funds.
Diana Karpman was the national coordinator in Sweden of the international trial of eculizumab (Alexion Pharmaceuticals) during 2009–2010. Lisa Sartz is the current national coordinator of the Alexion aHUS registry in Sweden.
- 1.Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int 76:534–545PubMedCrossRefGoogle Scholar
- 4.Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP (2011) Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 43:321–327PubMedCrossRefPubMedCentralGoogle Scholar
- 5.Watanabe S, Yamaguchi Y, Suzuki T, Ikezoe M, Matsumoto N, Chikamoto H, Nagafuchi H, Horita S, Hattori M, Shiraga H, Tokumoto T, Tanabe K, Toma H, Ito K (2001) Inherited factor H dysfunction and complement-associated glomerulonephritis in renal grafts of first and second transplantations. Clin Transplant 15[Suppl 5]:45–50PubMedCrossRefGoogle Scholar
- 8.Stangou M, Alexopoulos E, Pantzaki A, Leonstini M, Memmos D (2008) C5b-9 glomerular deposition and tubular alpha3beta1-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy. Scand J Urol Nephrol 42:373–380PubMedCrossRefGoogle Scholar
- 10.Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR (2006) Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 17:1724–1734PubMedCrossRefGoogle Scholar